Axon Enterprise, Inc $AXON Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lifted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 39.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,945 shares of the biotechnology company’s stock after purchasing an additional 2,533 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Axon Enterprise were worth $6,419,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hemington Wealth Management grew its holdings in shares of Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 17 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 27 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Axon Enterprise in the second quarter worth $37,000. NewSquare Capital LLC increased its position in shares of Axon Enterprise by 96.2% during the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 25 shares during the period. Finally, Washington Trust Advisors Inc. raised its stake in shares of Axon Enterprise by 44.7% in the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $631.69 on Friday. The firm has a market capitalization of $49.85 billion, a P/E ratio of 199.90, a P/E/G ratio of 19.89 and a beta of 1.41. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. The firm’s 50 day moving average is $572.86 and its two-hundred day moving average is $688.07.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same quarter in the prior year, the firm posted $1.45 EPS. The firm’s quarterly revenue was up 30.6% compared to the same quarter last year. Research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $619.01, for a total value of $6,190,100.00. Following the completion of the transaction, the chief executive officer owned 3,100,997 shares in the company, valued at $1,919,548,152.97. This represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $550.63, for a total value of $55,063.00. Following the sale, the director owned 1,316 shares in the company, valued at $724,629.08. This trade represents a 7.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 60,540 shares of company stock valued at $34,684,738 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on AXON. The Goldman Sachs Group lowered their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. UBS Group cut their target price on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Barclays reduced their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Morgan Stanley lowered their price target on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $805.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.